These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10351145)

  • 21. Logistical problems of supplying leucodepleted blood components within the national blood service.
    Tandy N
    Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160
    [No Abstract]   [Full Text] [Related]  

  • 22. Leukocyte depletion for safe blood transfusion.
    Singh S; Kumar A
    Biotechnol J; 2009 Aug; 4(8):1140-51. PubMed ID: 19418471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic effects of leukocytes present in transfused cellular blood products.
    Bordin JO; Heddle NM; Blajchman MA
    Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion.
    Turner M
    Transfus Sci; 1998 Dec; 19(4):331-2. PubMed ID: 10351147
    [No Abstract]   [Full Text] [Related]  

  • 26. Relative efficiency of leucocyte removal procedures for the production of leucocyte-poor red cell concentrates assessed by flow cytometry.
    Farrugia A; Tan Y; Romeo A; Martin L; Rolland JR; Kellner S; Piouronowski H
    Vox Sang; 1994; 66(3):153-60. PubMed ID: 8036782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Leucocyte removal and its clinical application].
    Zhao SM; Lin WC; Liu JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):478-82. PubMed ID: 12513754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters.
    Ten Haaft MA; Van den Berg-Loonen PM; Van Rhenen DJ
    Vox Sang; 1992; 63(4):257-61. PubMed ID: 1481473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International views on universal leucodepletion: the perspective in Germany.
    Seitz MD
    Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155
    [No Abstract]   [Full Text] [Related]  

  • 30. Operational and research approaches to universal leucodepletion in Scotland.
    Prowse C
    Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158
    [No Abstract]   [Full Text] [Related]  

  • 31. [The present status of blood filtration--fundamentals and the clinical significance of leukocyte depletion and microaggregate filters in blood transfusion].
    Hitzler W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1993 Oct; 28(6):341-51. PubMed ID: 8251599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical applications of leukocyte filters].
    Bordin JO; Fabron Júnior A
    Rev Assoc Med Bras (1992); 1997; 43(3):205-8. PubMed ID: 9497547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-storage leucocyte depletion and transfusion reaction rates in cancer patients.
    Da Ponte A; Bidoli E; Talamini R; Steffan A; Abbruzzese L; Toffola RT; De Marco L
    Transfus Med; 2005 Feb; 15(1):37-43. PubMed ID: 15713127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inline-filtration.
    Karger R; Kretschmer V
    Transfus Apher Sci; 2002 Oct; 27(2):137-52. PubMed ID: 12350049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NBS approaches to the approval of suppliers of leucodepletion systems.
    Smith KJ
    Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159
    [No Abstract]   [Full Text] [Related]  

  • 36. Leukocyte-reduced blood components: patient benefits and practical applications.
    Higgins VL
    Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International views on universal leucodepletion: the perspective in Portugal.
    de Sousa G
    Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152
    [No Abstract]   [Full Text] [Related]  

  • 38. Canadian Red Cross Society symposium on leukodepletion: report of proceedings.
    Freedman JJ; Blajchman MA; McCombie N
    Transfus Med Rev; 1994 Jan; 8(1):1-14. PubMed ID: 7907899
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of leukodepletion in the control of transfusion-transmitted disease.
    Goldman M; Delage G
    Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040
    [No Abstract]   [Full Text] [Related]  

  • 40. International views on universal leucodepletion: the perspective in NBS, Ireland.
    Murphy W
    Transfus Sci; 1998 Dec; 19(4):349-50. PubMed ID: 10351151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.